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Purpose:  A  sustained  gene  modulatory  strategy  is  necessary  for  regulating  abnormal  gene  expression  in  diabetic
retinopathy, a long-term complication. We investigated the efficacy of a small interference RNA (siRNA) strategy in
mediating the long-term downregulatory effect of fibronectin (FN) overexpression in vivo.
Methods: Streptozotocin-induced diabetic rats were intravitreally injected with 3 µM of FN-siRNA at six week intervals
over a period of 4.5 months. Retinal FN protein expression, vascular basement membrane (BM) thickness, and retinal
vascular cell loss were assessed by western blot, electron microscopy, and retinal trypsin digest, respectively.
Results: Retinal FN expression and BM thickness were significantly increased in diabetic rat retinas compared to those
in non-diabetic control rats (188±14.2% of control versus 100±7.4% of control, p<0.002; 72.5±5.0 nm versus 51.5±4.8
nm, p<0.001, respectively). FN-siRNA treatment reduced FN overexpression and BM thickening (145±19.9% of control
and 56.4±2.8 nm, respectively) and significantly reduced the number of acellular capillaries (35%) and pericyte loss (55%)
compared to those of untreated diabetic eyes.
Conclusions: These findings suggest that BM thickening is an important target for preventing vascular cell loss in a
diabetic retina, and that the siRNA approach could be useful for long-term gene modulation in diabetic retinopathy.
Retinal capillary basement membrane (BM) thickening
is closely associated with the development of vascular lesions
in diabetic retinopathy, a long-term complication of diabetes.
The detrimental effects of BM thickening in promoting the
development of vascular lesions in diabetic retinopathy are
beginning  to  be  established.  Studies  indicate  that  BM
thickening  primarily  develops  from  a  process  involving
hyperglycemia-induced excess synthesis of BM components,
such as fibronectin (FN), collagen type IV, and laminin [1–
4]. The abnormal thickening of BM in the retinal capillaries
is a long-lasting lesion of diabetic retinopathy and appears to
promote  other  characteristic  lesions,  including  acellular
capillaries  and  pericyte  loss,  vascular  leakage,  and  a
disruption of the overall vascular homeostasis associated with
diabetic retinopathy [1,5,6]. An effective long-term strategy
to block retinal capillary BM thickening could be useful as a
therapeutic intervention for preventing the damaging lesions
resulting from diabetic retinopathy.
The role of FN overexpression and BM thickening has
recently  been  examined  in  the  retinal  and  glomerular
capillaries of diabetic rats using antisense oligonucleotides
[7].  The  study  demonstrated  that  tight  glycemic  control
downregulates FN overexpression and reduces vascular BM
thickening in retinal and renal tissues [7]. Previously, we have
shown that among various BM components, downregulation
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of FN expression alone significantly reduces BM thickening
and  inhibits  the  development  of  acellular  capillaries  and
pericyte  loss  in  the  retinas  of  galactose-fed  rats  [6].
Furthermore,  the  reduction  of  FN  overexpression  using
siRNA has indicated improved cell monolayer permeability
(Toshi  siRNA).  Overall,  these  findings  indicate  the
importance of FN in mediating the barrier characteristics of
the BM structure, and suggest that a strategy for reducing FN
overexpression  could  be  beneficial  for  improving  retinal
vascular lesions.
We  previously  demonstrated  that  antisense
oligonucleotides could reduce BM thickening by lowering the
expression of BM components [6], and that downregulation
of BM components in the retina have beneficial effects in
inhibiting blood retinal barrier breakdown [1]. Our findings
proved that a thickened retinal capillary BM could be targeted
for  therapeutic  intervention  and  that  preventing
overexpression  of  BM  components  may  delay,  or  even
prevent, the development of the vascular lesions characteristic
in diabetic retinopathy. However, our report [6] showed that
the implementation of an antisense oligonucleotide strategy
for  the  treatment  of  diabetic  retinopathy  would  require
multiple intravitreal injections, thus making it impractical for
a  long-term  complication  such  as  diabetic  retinopathy.  A
siRNA strategy has been reported to have a longer duration of
efficacy than the antisense oligonucleotides [8], so we tested
its long-term efficacy in preventing BM overexpression and
thickening in the retinal capillaries of diabetic rats.
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3166In this study, we selectively targeted FN since previous
studies  indicated  that  downregulation  of  FN  expression
significantly  reduces  retinal  capillary  BM  thickening  and
prevents  retinal  vascular  lesions  characteristic  of  diabetic
retinopathy [6]. The siRNA approach effectively sustains a
reduction  in  high  glucose-induced  FN  overexpression  in
microvascular endothelial cells in cultures [9], and FN-siRNA
exhibits  long-term  efficacy  in  downregulating  FN
overexpression  in  vitro.  Therefore  in  this  study,  we
investigated the in vivo efficacy of FN-siRNA as a long-term
modulatory strategy by assessing its safety and tolerability; its
localization in targeted retinal vascular cells; its ability to
reduce specific gene (FN) expression on a long-term basis in
retinal  vascular  cells;  and  its  ability  to  prevent  the
development  of  acellular  capillaries  and  pericyte  loss  in
diabetic rats, two prominent vascular lesions characteristic of
diabetic retinopathy.
METHODS
Dose  response  study  of  intravitreally  injected  FN-siRNA:
Different concentrations of FN-siRNA (0.5, 1, 3, or 6 µM)
were  tested  for  1  week  to  identify  an  effective  dose  for
reducing FN expression by approximately 30%. The target for
achieving 30% downregulation was selected based on our
previous studies, which is consistent with the magnitude of
the  increase  caused  by  diabetes.  As  such,  a  30%–50%
decrease in FN expression would bring diabetic levels to a
normal range [10].
Time course study of intravitreally injected FN-siRNA: To
determine the duration efficacy of the FN-siRNA strategy in
reducing FN expression, retinas of rats intravitreally injected
with 3 μM of FN-siRNA were studied at different time points
(3 days, 1, 2, 3, and 6 weeks). The retinal proteins from rats
sacrificed at these time points were analyzed for their FN
protein level, which was then compared to that of uninjected
control rats.
Streptozotocin-induced  diabetic  rats  and  FN-siRNA
intravitreal injection: In this study, 32 male Sprague Dawley
rats  were  randomly  assigned  into  four  groups:  normal,
diabetic,  diabetic  injected  with  FN-siRNA,  and  diabetic
injected with scrambled siRNA. Diabetes was induced using
streptozotocin (STZ) as previously described [7]. SiRNA was
administered intravitreally every six weeks over the study
period of six months, for a total of three injections. Intravitreal
injections were performed behind the ora serrata in the pars
plana, directly into the vitreal cavity. Intravitreal injections
were performed at an acute angle of about 30°, with a 30 gauge
needle. The penetrance of the needle during the intravitreal
injection was about 1 mm. Ten µl of freshly prepared 3 µM
siRNA was injected every six weeks; that is, at the 1.5, 3, and
4.5 month time points. At the end of six months, all animals
were sacrificed by CO2 inhalation as described and approved
by the Boston University School of Medicine animal care
board. No untoward effects were noted from the intravitreal
injections in any of the eyes, as there was no redness or opacity
as  determined  through  routine  eye  examinations,  as
previously tested [11]. One eye from each animal was used
for western blot analysis to determine the FN protein level,
while the contralateral eye was subjected to retinal trypsin
digestion  (RTD)  to  isolate  the  retinal  vasculature.  These
isolated  retinal  vasculatures  were  then  stained  with
hematoxylin  and  periodic  acid-Schiff  (PAS)  and  were
analyzed  for  retinal  vascular  lesions.  Additionally,  dose
response and time course studies were performed using four
animals  for  each  dose  or  time  point.  Blood  glucose,
bodyweight, and HbA1c levels were monitored throughout
the study and insulin injections were administered as required
to maintain bodyweight and avoid ketoacidosis.
Localization of FN-siRNA in retinal vascular cells: The 21-
mer  FN-siRNA  (5′-AAC  TTC  AAA  TTA  TGA  ACA
AGA-3′) used in this study was designed on the basis of
Tuschl’s  rules  (AAC19  adjacent  nucleotides)  [12]  and
encompassed the translation initiation site of the FN transcript
as described. It was previously tested in vitro for its efficacy
against FN overexpression [9]. To avoid any length-related
nonspecificity,  we  used  non-specific  scrambled  siRNA,
niR16 of a similar length (5′-AAU AUU GGC GUU AAG
AUU CUA- 3′), as a control in this study. Localization and
distribution  of  FN-SiRNA  in  rat  retinas  was  assessed  by
intravitreally injecting Cy3-labeled FN-siRNA and observing
localized fluorescence in rat retinal sections at different time
points (2 h, 6 h, and 4 days) post intravitreal injection. Retinal
sections from rat eyes injected with Cy3-labeled scrambled
siRNAs exhibited a similar distribution pattern to those of FN-
siRNA at all time points observed. However, the biologic
effect of the scrambled siRNA compared to that of the FN-
siRNA was markedly different, with practically no effect on
FN expression in rat retinas.
Electron microscopy: Retinas isolated from enucleated eyes
were immediately fixed in 2.5% glutaraldehyde in a 0.1 M
cacodylate buffer. The tissues were dehydrated using osmium
tetraoxide, ethanol, and propylene oxide (EMS, Hatfield, PA).
The tissues were then embedded in an Epon-Araldite plastic
mixture and baked for 48 h. Ultra-thin sections were serially
cut at 60–70 nm using a microtome (LKB Ultratome Nova,
Bromma, Sweden). The sections were collected and placed on
a copper grid and stained with 4% uranyl acetate (EMS) in
methanol  and  viewed  under  a  transmission  electron
microscope  (Philips,  Electron  Optics,  Eindhoven,
Netherlands). At least ten random images of retinal capillaries
from the outer plexiform and ganglion cell layers from each
individual animal were photographed and enlarged to 50,000×
magnification for examination. These electron micrographs
were analyzed according to the orthogonal intercept method
[13] for BM thickness.
Measurement  of  retinal  capillary  basement  membrane
thickness and retinal histopathology: Retinal capillary BM
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3167Figure 2. Dose response study showing fibronectin (FN)–siRNA
efficacy. Different doses of FN-siRNA were tested at a 1-week time
point to identify an optimal dosage for effective downregulation of
FN expression. The graph shows reduced FN levels in rat retinas after
intravitreal injection with increasing concentrations (0.5–6.0 μM) of
FN–SiRNA. A 3 μM dose was most effective at downregulating
retinal FN protein expression. *=p<0.05 versus “0 μM” group mean;
n=4/group.
Figure  3.  Time  course  study  showing  fibronectin  (FN)–SiRNA
efficacy. Relative levels of FN protein in rat retinas at different time
points (3 days–6 weeks) after intravitreal injection of 3 μM FN–
siRNA. By the 1-week time point, retinal FN protein expression was
significantly reduced and remained inhibited at the 6-week time
point. Scrambled siRNA showed no effect on the FN protein level.
*=p<0.05 versus “0 days” group mean; n=4/group.
Figure 1. Localization of intravitreally injected fibronectin (FN)-SiRNA in vascular cells of a rat retina. FN-siRNA injected intravitreally in
rat eyes localized on the inner limiting membrane and in retinal microvessels. The arrow points to a microvessel showing an endothelial cell
nucleus (4',6-diamidino-2-phenylindole [DAPI]-positive) in panel A, and panel B shows Cyanine-3 labeled FN-siRNA localized in the same
endothelial cell of the retinal microvessel. Panel C shows a superimposed image of A and B. Panel D shows a close-up view of the retinal
microvessel shown in panel C. Bar: 50 μm. Inner limiting membrane (ILM); Retinal capillary (RC).
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3168thickness was determined from electron micrographs using
the Siperstein method [13]. In brief, using a computer with
Adobe Systems Inc., San Jose, CA, a 20-spoke radial grid was
superimposed  over  each  capillary  micrograph,  and  the
thickness  of  the  BM  was  measured  at  the  point  where  it
intersected  with  a  spoke.  The  widths  of  the  two  thinnest
portions  of  the  BM  surrounding  each  capillary  were  also
measured. Most BM width measurements were performed on
capillaries from the outer plexiform layer of the mid retina. At
least ten capillaries were photographed and measured from
each of the ten retinal sections per animal to determine the
capillary BM thickness. Areas of the BM in which pericytes
overlapped with endothelial cells were excluded from the
analysis. Data was collected and evaluations were performed
in a masked manner to hide the identity of the rats.
Isolation  and  assessment  of  pericyte  loss  and  acellular
capillaries: To analyze the retinal vasculature for pericyte loss
and acellular retinal capillaries, we used the retinal trypsin
digest (RTD) technique as described by Kuwabara and Cogan
[14] with minor modifications. Briefly, after enucleation, eyes
were fixed in 10% formalin, intact retinas were dissected out
and subjected to 3% trypsin digestion at 37 °C for 2–3 h with
gentle  shaking.  Under  the  dissecting  microscope,  the
nonvascular  mass  was  removed  from  the  entire  vascular
network and was then mounted and stained with PAS (Sigma-
Aldrich, St. Louis, MO) and hematoxylin. The slides were
immersed in 0.5% periodic acid (Sigma) for 10 min, rinsed in
water, and reacted in Schiff’s reagent (Sigma) for 10 min.
After a water rinse, the slides were dipped in acid ethanol (1%
HCl, Sigma), rinsed, and reacted in 1% LiCO3 (Sigma). After
dehydration in ethanol and clearing in xylene, the slides were
mounted with Permount. The PAS stained the glycoprotein of
the BMs pink, while the cellular nuclei (elliptical and oriented
along  the  circumference  of  the  capillary  cross-section  for
endothelial cells; round in shape and abutting the outer portion
of the capillary wall for pericytes) were stained blue by the
hematoxylin. Representative areas of the vascular network
were photographed using a Nikon DS-Fi1(Nikon Instruments,
Melville,  NY).  The  images  were  analyzed  for  retinal
morphology and in particular for pericyte loss and acellular
capillaries.
Estimation  of  pericyte  loss  and  acellular  capillaries:
Approximately 1,200 capillary cells were counted from the
midretinal  area  of  each  retina  following  RTD  and
hematoxylin-PAS  staining.  At  first,  the  images  of  retinal
capillaries  were  captured  using  a  Kodak  digital  camera
connected  to  a  computer  and  then  pericyte  counts  were
determined from the images. The specific loss of pericytes
could be detected from the empty “shell” left behind after
pericyte “dropout.” Capillaries that lacked both pericytes and
endothelial cells were considered acellular. A defined area
Figure  4.  Effect  of  fibronectin  (FN)-
siRNA on retinal FN protein expression.
A: Representative western blot image
with an internal loading control β–actin
showing  the  effect  of  FN-siRNA  on
retinal FN protein expression in diabetic
rats. FN-siRNA treatment in the diabetic
rats  specifically  reduced  retinal  FN
protein expression compared to that in
uninjected  diabetic  rats.  B:  Graphical
representation  of  retinal  FN  protein
expression  in  four  groups  of  rats—
normal, diabetic, diabetic injected with
FN-siRNA, and diabetic injected with
scrambled  siRNA—showing  that  an
intravitreal  injection  of  FN-siRNA
significantly  reduces  FN  protein
expression  in  diabetic  rat  retinas.
Normal  versus  Diabetic  *=p<0.05;
Diabetic  versus  Diabetic+FN-siRNA
**=p<0.05, n=8.
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3169(1 mm2) was analyzed for each of the treated and untreated
groups to compare the number of acellular capillaries.
Statistical analysis: The data are reported as the means±SD.
Dunnett’s comparison was only used against the control to
analyze the data presented in Figure 1, Figure 2, and Figure
3. One-way ANOVA followed by a Student–Newman–Keuls
test was used to analyze data in Figure 4, Figure 5, Figure 6,
and Figure 7. Data with values of p<0.05 were considered
significant.
RESULTS
Localization of FN-SiRNA in rat retinal vascular cells after
intravitreal injection: Retinal sections of the intravitreally
injected Cy3-labeled FN-siRNA performed together with 4',
6-diamidino-2-phenylindole  (DAPI)  were  examined  using
confocal microscopy. FN-siRNA localization in the retinal
vascular cells of the rat eyes was observed within 2 h post-
injection. Based on the double stain from Cy3 and DAPI,
fluorescence from the siRNA could be assigned to the nuclei
of retinal vascular endothelial cells and pericytes (Figure 1A-
D). The luminally located endothelial cell was distinguished
from  the  abluminally  located  pericytes  by  its  elongated
nucleus.
Dose  response  study  showing  FN-SiRNA  efficacy:  The
effectiveness  of  the  FN-siRNA  strategy  was  tested  using
increasing concentrations (0.5–6.0 µM) of siRNA to identify
an optimal dose for ~30% downregulation of FN expression.
A  reduced  FN  level  was  observed  in  rat  retinas  after
intravitreal injection at concentrations ≥1 μM at 1 week post-
injection  (Figure  2).  The  1  µM,  3  µM,  and  6  µM  dose
significantly  reduced  FN  expression  (79±11%  of  control,
p=0.03; 68±7% of control, p=0.01; 73±9% of control, p=0.02,
respectively).
Time course study showing FN-SiRNA efficacy: A time course
(0–6  weeks)  study  following  intravitreal  injection  of  FN-
siRNA showed significant downregulation of FN expression
in the retinas. After 1 week, retinal FN expression was reduced
by approximately 35%, which persisted to the 6 week time
point (Figure 3). Scrambled siRNA showed no effect on the
retinal FN protein level at any time point and showed no
significant difference between the control (uninjected eyes)
and the eyes injected with FN-siRNA.
Effect of FN-SiRNA on retinal FN protein level: Western blot
analyses indicated a significant increase in FN expression in
the retinas of diabetic rats compared to those of non-diabetic
control  rats  (188±14.2%  of  control  versus  100±7.4%  of
control, p<0.002), respectively. A significant downregulation
in FN expression was observed in the retinas of diabetic rats
that were intravitreally injected with FN-siRNA compared to
those of uninjected diabetic control eyes or those of diabetic
eyes injected with scrambled siRNA (145±19.9% of control
versus 188±14.2% of control, p=0.03; 145±19.9% of control
versus  183±15%  of  control,  p=0.03,  respectively;  Figure
4A,B).
Effect of reduced FN on retinal capillary basement membrane
thickness:  An  electron  microscopy  analysis  showed  a
significant increase (~40%) in retinal capillary BM thickness
in the diabetic rats compared to those of non-diabetic control
Figure 5. Electron microscopy (EM) analysis of capillary basement membrane (BM) thickening in rat retinas. A-D: Effect of fibronectin (FN)-
siRNA on retinal capillary BM thickening in diabetic rats. Representative EM images of transverse sections of retinal capillaries of (A) normal
rat, (B) diabetic rat, (C) diabetic rat intravitreally injected with FN-siRNA, and (D) diabetic rat intravitreally injected with scrambled siRNA;
scale bar=1 μm. Enlarged views: E-H; scale bar=100 nm. FN-siRNA treatment in the diabetic rats specifically prevented BM thickening
(arrowheads) compared to uninjected diabetic rats. (I) Graphical representation of retinal vascular BM thickness in four groups of rats: normal,
diabetic, diabetic injected with FN-siRNA, and diabetic injected with scrambled siRNA, showing that an intravitreal injection of FN-siRNA
reduces retinal capillary BM thickening in diabetic rats. Normal versus Diabetic *=p<0.05; Diabetic versus Diabetic+FN-siRNA **=p<0.05,
n=8.
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3170rats  (72.5±5.0  nm  versus  51.5±4.8  nm,  p<0.001).  Upon
intravitreal injection with FN-siRNA, a significant reduction
(~75%) in retinal capillary BM thickness was observed in the
retinas of diabetic rats compared to those of uninjected control
diabetic  rats  and  diabetic  rats  intravitreally  injected  with
scrambled siRNA (56.4±2.8 nm versus 72.5±5.0 nm, p=0.03;
56.4±2.8 nm versus 73.7±3.9 nm, p<0.01, respectively; Figure
5A-I).
Effect of FN-SiRNA on the development of vascular lesions:
In this study, we assessed two characteristic lesions of diabetic
retinopathy—pericyte loss and acellular capillaries—both of
which showed significant improvement in retinas treated with
FN-siRNA. The increased pericyte loss (151±18%, p=0.02 of
the control) and number of acellular capillaries (175±16%,
p=0.01  of  the  control)  observed  in  diabetic  retinas  was
significantly reduced in retinas of diabetic rats treated with
FN-siRNA (pericyte loss: 115±11%, p=0.02 of the control;
acellular capillaries: 118±9%, p=0.01 of the control). The
number of acellular capillaries (Figure 6A-E) and the pericyte
loss (Figure 7A-E) in diabetic rats that received scrambled
siRNA did not differ from those of the diabetic rats. There was
a  strong  correlation  between  decreased  pericyte  loss  and
reduced  BM  thickening  (r=0.71),  as  well  as  between  a
decreased number of acellular capillaries and reduced BM
thickening (r=0.82).
Efficacy and safety of long-term application of FN-SiRNA:
Retinas injected with siRNA and examined 1, 2, 4, and 6
weeks post-injection showed no physical evidence of redness
or opacity in the eyes, and retinal capillaries and sections
examined in parallel showed no infiltration of macrophages.
Blood glucose, bodyweight, and HbA1c levels: Fasting blood
glucose levels were measured every alternate day and showed
hyperglycemic conditions in diabetic animals (307±48 mg/dl)
compared to normal animals (122±21 mg/dl). The HbA1c
level measured at the three-month interval also confirmed a
hyperglycemic state in diabetic animals (11.2±1.6%) versus
normal animals (5.3±1.1%; Figure 8). A reduced bodyweight
was  observed  in  the  diabetic  animals,  which  indicates  a
diabetic condition in these animals.
DISCUSSION
In this study, we demonstrated that the FN-siRNA approach
is effective in downregulating overexpression of FN, a BM
component, and that it resulted in beneficial effects, including
a  significant  reduction  of  vascular  BM  thickening  in  the
diabetic  retina.  The  results  from  this  study  suggest  that
hyperglycemia-induced overexpression of FN plays a critical
role  in  the  development  of  capillary  BM  thickening  in
experimental diabetic animals. This study reports that an FN-
siRNA  strategy  is  effective  in  preventing  hyperglycemia-
induced  BM  thickening  in  retinal  capillaries.  To  our
Figure 6. Development of acellular capillaries in the diabetic retina. A-D: Representative retinal trypsin digest (RTD) images showing the
effect of fibronectin (FN)-siRNA on the development of acellular capillaries (as indicated by arrows) in retinas of a (A) normal rat, (B) diabetic
rat, (C) diabetic rat intravitreally injected with FN-siRNA, and (D) diabetic rat intravitreally injected with scrambled siRNA. FN-siRNA
treatment in the diabetic rats specifically reduced the development of acellular capillaries compared to those of uninjected diabetic rats. E:
Graphical representation of acellular capillaries in four groups of rats: normal, diabetic, diabetic injected with FN-siRNA, and diabetic injected
with scrambled siRNA, showing that an intravitreal injection of FN-siRNA reduces the development of acellular capillaries in diabetic rat
retinas. Normal versus Diabetic *=p<0.05; Diabetic versus Diabetic+FN-siRNA **=p<0.05, n=8.
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3171knowledge, no study has yet been conducted that examines
the efficacy of a siRNA strategy in reducing capillary BM
thickening in the diabetic retina and its subsequent effects.
In  the  present  study,  we  demonstrated  that
overexpression of FN in retinal vascular cells of diabetic rats
Figure  8.  HbA1c  levels  in  experimental  animals.  HbA1c  levels
measured at the end of the study confirmed hyperglycemic status in
diabetic animals. Diabetic animals injected with fibronectin (FN)-
siRNA or scrambled siRNA also displayed a similar hyperglycemic
condition. *=p<0.05 versus “Normal” group mean; n=8/group.
was inhibited by intravitreal injection(s) of FN-siRNA, which
resulted in a reduction in BM thickness and other beneficial
outcomes,  including  the  prevention  of  pericyte  loss  and
acellular  capillaries.  This  finding  was  consistent  with  our
previous results demonstrating that reducing overexpression
of BM components can decrease BM thickening in retinal
capillaries [6]. The present results showed that inhibition of
BM  thickening  using  a  siRNA  strategy  prevented  retinal
vascular cell loss, thus suggesting that overexpression of BM
components promotes BM thickening and cell loss, and that
FN-siRNA is an effective preventative strategy. Although it
is unclear how BM thickening promotes cell loss, our previous
report suggested that the extracellular matrix (ECM) produced
by endothelial cells grown in high glucose condition promotes
apoptosis [15].
BM is a highly organized structure composed of multiple
ECM components linked to each other in an orderly manner.
The  ordered  structure  appears  to  be  compromised  in  the
thickened BMs of diabetic retinal capillaries, as evidenced by
altered  ultrastructures  such  as  a  “Swiss  cheese-like”
appearance. These altered structures are at least in part due to
a  disturbed  ratio  among  the  ECM  components  –  a  likely
consequence of the abnormal increase in synthesis of the ECM
components [6,10,16–24]. Our finding that BM thickening is
ameliorated by FN-siRNA suggests that a siRNA strategy
Figure 7. Retinal pericyte loss in diabetic rats. A-D: Representative retinal trypsin digest (RTD) images showing the effect of fibronectin (FN)-
siRNA on the development of pericyte ghosts (as indicated by arrows) in retinas of a (A) normal rat, (B) diabetic rat, (C) diabetic rat
intravitreally injected with FN–siRNA, and (D) diabetic rat intravitreally injected with scrambled siRNA. FN-siRNA treatment in the diabetic
rats specifically reduced pericyte loss compared to uninjected diabetic rats. E: Graphical representation of pericyte dropouts in four groups
of rats—normal, diabetic, diabetic injected with FN-siRNA, and diabetic injected with scrambled siRNA—showing that an intravitreal
injection of FN-siRNA reduces the pericyte loss in diabetic rat retinas. Normal versus Diabetic *=p<0.05; Diabetic versus Diabetic+FN-siRNA
**=p<0.05, n=8.
Molecular Vision 2011; 17:3166-3174 <http://www.molvis.org/molvis/v17/a341> © 2011 Molecular Vision
3172could  be  useful  in  preventing  vascular  abnormalities
associated with diabetic retinopathy.
One  mechanism  responsible  for  triggering  apoptotic
signaling is the high glucose- or diabetes-induced forkhead
box protein 1 (FOXO1) activation [25]. A previous study
indicates that upon cell-matrix adhesion, beta-1 integrin can
trigger the activation of the PI3K/Akt pathway, which then
leads to the displacement of FOXO1 from a target promoter
[25–27].  Clearly,  communication  between  cells  and  the
thickened BM is hampered, which can result in the promotion
of apoptosis.
Previously, we identified a FN-siRNA that exhibits a
long-term effect in microvascular endothelial cells, in vitro
[9]. Time course studies with the same siRNA conducted in
rat retinas indicated a significant decrease in FN expression
that lasted for six weeks. We also determined the long-term
efficacy of a FN-siRNA strategy—over a six month period
with  injections  at  1.5,  3,  and  4.5  months—in  preventing
characteristic FN overexpression and retinal vascular lesions
in  retinas  of  diabetic  rats.  This  regimen  provides  a  50%
improvement  over  a  monthly  antisense  oligonucleotides
regimen. In the long term, the benefits include a significant
reduction in the number of injections. The results from this
study suggest that the siRNA approach may have a potential
long-term effect against the development of vascular lesions
associated with diabetic retinopathy. Moreover, the consistent
finding  that  FN-siRNA  was  efficacious,  while  scrambled
siRNA had no effect, suggests that the results were not due to
non-specific effects.
The  FN  siRNA  used  in  this  study  was  specifically
targeted  to  the  FN  translation  initiation  site  of  the  FN
transcript, with the goal of reducing hyperglycemia-induced
FN  overexpression  by  50%.  Our  studies  indicate  that  an
approximate 50% FN reduction was achieved using the 21-
mer FN siRNA. However, it is possible that the efficacy may
be increased if longer (25–30 mer) siRNAs [28] are used. The
possibility of off-target effects may exist when siRNAs are
used. However, in this study, the 21-mer FN siRNA suited the
purpose and no off-target effects were detectable.
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